SBBP
Income statement / Annual
Last year (2020), Strongbridge Biopharma plc's total revenue was $30.73 M,
an increase of 41.54% from the previous year.
In 2020, Strongbridge Biopharma plc's net income was -$45.08 M.
See Strongbridge Biopharma plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$30.73 M |
$21.71 M |
$18.03 M |
$7.05 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$2.21 M
|
$3.82 M
|
$3.99 M
|
$1.48 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$28.52 M
|
$17.89 M
|
$14.04 M
|
$5.56 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.93
|
0.82
|
0.78
|
0.79
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$25.80 M
|
$30.90 M
|
$25.44 M
|
$17.27 M
|
$20.02 M
|
$20.14 M
|
$5.84 M
|
$2.53 M
|
| General & Administrative Expenses |
$40.87 M
|
$45.81 M
|
$63.34 M
|
$36.29 M
|
$14.88 M
|
$22.72 M
|
$4.59 M
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$40.87 M
|
$45.81 M
|
$63.34 M
|
$36.29 M
|
$14.88 M
|
$22.72 M
|
$4.59 M
|
$0.00
|
| Other Expenses |
$5.02 M
|
$5.02 M
|
$7.19 M
|
$5.02 M
|
$0.00
|
$0.00
|
$0.00
|
-$7.73 M
|
| Operating Expenses |
$71.68 M
|
$81.74 M
|
$95.96 M
|
$58.58 M
|
$34.90 M
|
$42.85 M
|
$10.43 M
|
-$5.19 M
|
| Cost And Expenses |
$73.90 M
|
$85.56 M
|
$99.95 M
|
$60.07 M
|
$34.90 M
|
$42.85 M
|
$10.43 M
|
$5.19 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1,000.00
|
$25,000.00
|
$0.00
|
$0.00
|
| Interest Expense |
$1.34 M
|
$0.00
|
$12.52 M
|
$4.31 M
|
$20,000.00
|
$3,000.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$5.11 M
|
$5.10 M
|
$7.23 M
|
$5.03 M
|
$10,000.00
|
$11,000.00
|
$6,000.00
|
$3,000.00
|
| EBITDA |
-$38.65 M |
-$42.58 M |
$52.14 M |
-$102.37 M |
-$51.21 M |
-$44.02 M |
-$10.14 M |
-$5.39 M |
| EBITDA Ratio |
-1.26
|
-1.96
|
2.89
|
-14.53
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-1.4
|
-2.94
|
-4.54
|
-7.52
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$1.93 M
|
$16.16 M
|
$114.31 M
|
-$58.69 M
|
-$16.46 M
|
-$1.23 M
|
$282,000.00
|
-$288,000.00
|
| Income Before Tax |
-$45.09 M
|
-$47.68 M
|
$32.39 M
|
-$111.71 M
|
-$51.36 M
|
-$44.08 M
|
-$10.15 M
|
-$5.48 M
|
| Income Before Tax Ratio |
-1.47
|
-2.2
|
1.8
|
-15.85
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$15,000.00
|
$1.77 M
|
$536,000.00
|
$1.77 M
|
-$2.64 M
|
-$450,000.00
|
-$480,000.00
|
-$93,000.00
|
| Net Income |
-$45.08 M
|
-$49.45 M
|
$31.85 M
|
-$113.48 M
|
-$48.60 M
|
-$43.58 M
|
-$9.67 M
|
-$5.30 M
|
| Net Income Ratio |
-1.47
|
-2.28
|
1.77
|
-16.11
|
0
|
0
|
0
|
0
|
| EPS |
-0.8 |
-0.89 |
0.64 |
-3.11 |
-2.26 |
-2.62 |
-0.96 |
-0.88 |
| EPS Diluted |
-0.8 |
-0.89 |
0.64 |
-3.11 |
-2.24 |
-2.62 |
-0.96 |
-0.88 |
| Weighted Average Shares Out |
$56.11 M
|
$55.38 M
|
$49.72 M
|
$36.54 M
|
$21.55 M
|
$16.61 M
|
$10.11 M
|
$6.02 M
|
| Weighted Average Shares Out Diluted |
$56.11 M
|
$55.38 M
|
$49.72 M
|
$36.54 M
|
$21.66 M
|
$16.61 M
|
$10.11 M
|
$6.02 M
|
| Link |
|
|
|
|
|
|
|
|
